 ImmunoGen Inc. shares IMGN, -3.82 jumped 7 in premarket trade Tuesday, after the company announced a license agreement with Eli Lilly Co. LLY, -0.03 of its Novel Camptothecin ADC Platform for up to 1.7 billion in potential payments. Camptothecins are a class of cancer drugs. 